Therapeutic immunization strategies for the control of HIV-1. (Q36238709)

13 August 2017

1 reference

title

Therapeutic immunization strategies for the control of HIV-1. (English)

1 reference

13 August 2017

1

Lucy Dorrell

1 reference

13 August 2017

publication date

1 August 2005

1 reference

Expert Review of Vaccines

13 August 2017

published in

1 reference

13 August 2017

volume

4

1 reference

13 August 2017

issue

4

1 reference

13 August 2017

page(s)

513-520

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Therapeutic vaccines for chronic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Cellular immune responses to HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

HIV preferentially infects HIV-specific CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Therapeutic dendritic-cell vaccine for simian AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Therapeutic Immunization with Dendritic Cells Loaded with Heat‐Inactivated Autologous HIV‐1 in Patients with Chronic HIV‐1 Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Viremia control following antiretroviral treatment and therapeutic immunizationduring primary SIV251 infection of macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.4.513

21 January 2018

Identifiers

DOI

10.1586/14760584.4.4.513

1 reference

13 August 2017

1 reference